Supernus Pharmaceuticals (SUPN) Current Deferred Tax Assets (2015)

Supernus Pharmaceuticals' (SUPN) quarterly Current Deferred Tax Assets came in at -$200000.0 in Q4 2015.

Supernus Pharmaceuticals (SUPN) Current Deferred Tax Assets (2015) Analysis & Trends

Supernus Pharmaceuticals (SUPN) has 1 years of Current Deferred Tax Assets data on file, last reported at -$200000.0 in Q4 2015.

On a quarterly basis, Current Deferred Tax Assets changed N/A year-over-year to -$200000.0 in Q4 2015; TTM through Dec 2015 was -$200000.0, a N/A change from a year earlier, with the FY2015 full-year figure at -$200000.0, changed N/A from the prior year.
Current Deferred Tax Assets for Q4 2015 stood at -$200000.0.
Over the last five years, Current Deferred Tax Assets for SUPN reached as high as -$200000.0 in Q4 2015 and fell as low as -$200000.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Supernus Pharmaceuticals	2.72 Bn	2.34 Bn	-

Download Data

Date	Value
Dec 31, 2015	-200,000.00
Dec 31, 2015	-200,000.00